Störung des faserigen Knochengewebes

Fibrous dysplasia of bone is an exceptionally rare neoplastic condition whose exact etiology remains elusive. When compared to other benign tumors, it constitutes roughly 8% of all documented cases. The disease exhibits no correlation with gender, ethnicity, or geographic location. Initial symptoms may manifest as early as childhood and persist throughout the individual's lifetime. Despite extensive research, the precise underlying mechanisms of fibrous dysplasia development remain unclear. Genetic studies have demonstrated that the mutation is not hereditary, indicating that offspring of affected individuals typically do not inherit the genetic defect. The core issue stems from an abnormal protein structure that disrupts the process of bone cell formation.

Fibrous dysplasia of bone is a condition in which bone cavities become filled with fibrous tissue. Due to the previously described disruption in protein structure, the bone synthesis mechanism is impaired, while the body attempts to maintain functional continuity. Consequently, the resulting defects are filled with fibrous elements. Based on the nature of the symptoms, three primary types of fibrous dysplasia are recognized. The first is the monoostotic form, which affects a single bone and accounts for approximately 70% of all cases. This condition typically involves a solitary bone, such as the ribs, femur, tibia, skull, or mandible. It is noteworthy that this form of dysplasia carries the most favorable prognosis. The second type is the polyostotic or multiostotic dysplasia, which affects multiple bones and constitutes about 25% of cases. Similar to the monoostotic form, dysplasia can develop in various parts of the skeleton, ranging from the skull to the pelvis and limbs. In contrast to the monoostotic form, the polyostotic type is characterized by greater joint mobility restriction and increased susceptibility to mechanical injuries. Polyostotic dysplasia offers a less favorable prognosis due to the more intense and destructive nature of the disease. The third and final form is fibro-osteo-endocrine dysplasia, associated with hormonal changes. This form is more common in women and often co-occurs with hyperthyroidism or Cushing's syndrome. At the structural level, changes typically develop unilaterally in the body, accompanied by skin discolorations resembling café-au-lait spots, a result of impaired pigmentation. What distinguishes fibro-osteo-endocrine dysplasia from earlier forms is its impact on sexual development. Bone changes and associated symptoms lead to hormonal imbalances, referred to as McCune-Albright syndrome.

It is essential to note that dysplasia is a condition that progresses silently over an extended period. Bone cancer can induce pathological changes in the body for years without being detected. Diagnosis relies on comprehensive imaging studies, including X-rays and computed tomography (CT). To refine the diagnosis, a biopsy from the affected bone is often required. Treatment is complex and tailored to the individual. Minor lesions and mild pain may only require monitoring, with pain relievers administered as needed. Bisphosphonates are frequently used to inhibit disease activity and alleviate symptoms. In advanced cases, surgical intervention may be necessary, involving bone grafting or resection of affected areas. External stabilization with bone cement or metallic implants may also be employed.